Invest in Future
@FutureEv4
Followers
515
Following
41K
Media
44
Statuses
3K
Discovering mostly techstock with high potential for future
Joined October 2020
Ohh
0
0
0
Is that good form $HIMS?
Both the CEO and CFO of $NVO have previously confirmed that Novo Nordisk has sufficient capacity to launch the Wegovy pill in the U.S. This is important because, unlike injectable Wegovy, the pill won’t face capacity constraints, reducing the risk of shortages that previously
0
0
0
$HIMS bull cycle ended in October and it’s been bleeding ever since ❌ For now, I’m letting it burn. I won’t touch it again until Monthly BX shows real signs of life. Worst case, we could see another ~30% down from here. My plan: stay patient and wait for a fresh entry signal
25
22
344
we will see $HIMS
@TheLAPurchaser BPC-157 and many other peptides were placed on the Category 2 bulk drug list in 2023 Pre-2023, pharmacies could compound these peptides *with doctor prescription* Post-2023, this has been prohibited which is why we now see so much “black market” activity Theoretically,
0
0
0
✨🇨🇳At Window of the World in Shenzhen, robots are performing kung fu live.
59
310
1K
me too $HIMS at 25 is a steal
0
0
0
Very interesting TI will use UBTech robots, while TI will supply the chips to UBTech Humanoid chips will become a significant part of TI's biz They are now forging long contracts
Chinese media reports that Texas Instruments has reached agreement w/ UbTech to use its Walker S2 robots in its production line. UbTech will also use more TI chips in its production. It's unclear just which TI production line will use UbTech robot. https://t.co/pB3QUXwHNZ
6
15
226
Not that good fit $HIMS
BofA reiterates their $32 $HIMS price target with a SELL rating November sales remained steady, but orders continued to show weakness. Q4 will largely depend on December performance. Q4 Online revenue est $584–$609M, midpoint slightly below the street consensus of $608M. KPIs
0
0
0
😱
0
0
0
Wow, 2026 will be epic for $HIMS
$HIMS $LLY $NVO Over the past 1-2 months, The New York Times, The Economist, The Associated Press, The Guardian, CNN, and many other massive legacy media outlets have all run features on peptides 2026 is shaping up to be the year of peptides The year they move beyond early
0
0
0